<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Landing Page Homepage</title>
    <!-- BS CSS Stylesheet -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet"
        integrity="sha384-4bw+/aepP/YC94hEpVNVgiZdgIC5+VKNBQNGCHeKRQN+PtmoHDEXuppvnDJzQIu9" crossorigin="anonymous">
    <link rel="stylesheet" href="style.css">
    <!-- BS JS Stylesheet -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js"
        integrity="sha384-MrcW6ZMFYlzcLA8Nl+NtUVF0sA7MsXsP1UyJoMp4YLEuNSfAP+JcXn/tWtIaxVXM" crossorigin="anonymous"
        defer></script>

</head>

<body>
    <div class="roam-wrap">
        <img src="rencofilstat.gif" alt="The molecule Reconfilstat" id="roam1">
        <img src="rencofilstat.gif" alt="The molecule Reconfilstat" id="roam2">
        <img src="rencofilstat.gif" alt="The molecule Reconfilstat" id="roam3">
        <img src="rencofilstat.gif" alt="The molecule Reconfilstat" id="roam4">
    </div>
    <!-- Navbar section -->
    <nav class="navbar bg-dark">
        <div class="container navbar-dark">
            <a href="#" class="navbar-brand">NASH Drug Development</a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#nav2">
                <div class="navbar-toggler-icon"></div>
            </button>
            <div class="collapse navbar-collapse" id="nav2">
                <ul class="navbar-nav">
                    <li class="nav-item">
                        <a href="index.html" class="nav-link">HOMEPAGE</a>
                    </li>
                    <li class="nav-item">
                        <a href="article.html" class="nav-link">ARTICLES</a>
                    </li>
                </ul>
            </div>
        </div>
    </nav>
    <br>
    <!-- Content section -->

    <div class="container">
        <div class="card text-center">
            <div class="card-header">Latest Press Release</div>
            <div class="card-body">
                <h5 class="card-title">Passing of Key Safety Milestone in P2B ASCEND-NASH Trial of Rencofilstat
                </h5>
                <p class="card-text">The first planned DSMB meeting, occurred on schedule, and all labs, EKGs, adverse
                    events, and protocol deviations were reviewed, focusing on any potential safety signals from the
                    placebo-controlled trial.</p>
                <a href="https://www.globenewswire.com/en/news-release/2023/06/15/2688875/0/en/Hepion-Pharmaceuticals-Announces-Passing-of-Key-Safety-Milestone-in-Phase-2b-ASCEND-NASH-Trial-of-Rencofilstat.html"
                    class="btn btn-primary" target="_blank">Read Full</a>
            </div>
            <div class="card-footer text-body-secondary">June 15, 2023</div>
        </div>
    </div>
    <br>

    <div class="container box">
        <div class="row g-4">
            <div class="col-sm-6 mb-3 mb-sm-0">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Positive topline results from P2 ALTITUDE NASH.</h5>
                        <p class="card-text">ALTITUDE trial achieves primary and secondary endpoints, including
                            improvement in liver function and multiple NASH biomarkers.</p>
                        <a href="https://www.globenewswire.com/en/news-release/2023/05/22/2673221/0/en/Hepion-Pharmaceuticals-Phase-2-ALTITUDE-NASH-Trial-Achieves-Primary-and-Secondary-Endpoints-Including-Improvement-in-Liver-Function-and-Multiple-NASH-Biomarkers.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">May 22, 2023</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Updates on Ongoing P2 Clinical Program</h5>
                        <p class="card-text">Reviewing the status and tielines for the ongoing phase 2 NASH studies with
                            its lead drug candidate, Rencofilstat.</p>
                        <a href="https://www.globenewswire.com/news-release/2023/03/02/2619862/0/en/Hepion-Pharmaceuticals-to-Deliver-Updates-on-Ongoing-Phase-2-NASH-Clinical-Program-with-Rencofilstat-at-6th-Global-NASH-Congress.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">March 2, 2023</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Early Enrollment Completion for P2 ALTITUDE NASH</h5>
                        <p class="card-text">Completed enrollment of 60 NASH stage 3 subjects in the Phase 2 ALTITUDE
                            NASH clinical trial.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/12/05/2567480/0/en/Hepion-Pharmaceuticals-Announces-Early-Completion-of-Enrollment-in-Phase-2-ALTITUDE-NASH-Liver-Function-Trial.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">December 5, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Publication of P2A AMBITION Clinical Trial Results</h5>
                        <p class="card-text">Peer-reviewed journal, Hepatology Communications, has published a paper
                            reviewing the results of Hepion's AMBITION clinical trial.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/10/26/2541739/0/en/Hepion-Pharmaceuticals-Announces-Publication-of-Phase-2a-AMBITION-Clinical-Trial-Results.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">October 26, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Publication of Food Effect Study with Rencofilstat</h5>
                        <p class="card-text">Peer-reviewed journal, Clinical Pharmacology, has published the results of
                            a clinical trial examining the food effect with Rencofilstat.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/10/20/2538860/0/en/Hepion-Pharmaceuticals-Announces-Publication-of-Food-Effect-Study-with-Rencofilstat.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">October 20, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Initiation of Dosing in P2 ALTITUDE NASH</h5>
                        <p class="card-text">It has dosed the first NASH stage 3 patient with Rencofilstat. The trial is
                            being conducted in collaboration with HepQuant.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/09/12/2513995/0/en/Hepion-Pharmaceuticals-Announces-Initiation-of-Dosing-in-Phase-2-ALTITUDE-NASH-Liver-Function-Trial.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">September 12, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Initiation of P2B ASCEND NASH</h5>
                        <p class="card-text">It has screened the first subject in the ASCEND NASH clinical trial. The
                            trial is being conducted at up to 121 sites in 7 countries.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/08/31/2507575/0/en/Hepion-Pharmaceuticals-Announces-Initiation-of-Phase-2b-ASCEND-NASH-Trial.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">August 31, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Receives FDA Orphan Drug Status Designation for Rencofilstat for
                            Treatment of Hepatocellular Carcinoma</h5>
                        <p class="card-text">The U.S. FDA has granted Orphan Drug Designation to Rencofilstat.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/06/20/2465336/0/en/Hepion-Pharmaceuticals-Receives-FDA-Orphan-Drug-Status-Designation-for-Rencofilstat-for-the-Treatment-of-Hepatocellular-Carcinoma.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">June 20, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Clinical Collaboration with HepQuant in Phase 2B NASH trial</h5>
                        <p class="card-text">It has entered into a clinical collaboration with HepQuant, proprietary
                            investigational technology for evaluating liver function and health.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/05/03/2434467/0/en/Hepion-Pharmaceuticals-Announces-Clinical-Collaboration-with-HepQuant-in-Phase-2b-NASH-Trial.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">May 3, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">"Rencofilstat" as Nonproprietary Name for CRV431</h5>
                        <p class="card-text">The USAN Council has adopted the nonproprietary name "Rencofilstat" for the
                            company's lead drug candidates, CRV431.</p>
                        <a href="https://www.globenewswire.com/news-release/2022/01/06/2362840/0/en/Hepion-Pharmaceuticals-Announces-USAN-Selection-of-Rencofilstat-as-Nonproprietary-Name-for-CRV431.html"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">January 6, 2022</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">FDA Clearance of IND Application for CRV431 in the Treatment of Liver
                            Cancer</h5>
                        <p class="card-text">Hepion received FDA authorization of an IND to initiate the study of
                            Rencofilstat for the treatment of NASH.</p>
                        <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-fda-clearance-of-ind-application-for-crv431-in-the-treatment-of-liver-cancer/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">December 21, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
                        </h5>
                        <p class="card-text">Hepion has been granted Fast Track designation for, CRV431, for the
                            treatment of NASH
                        <p>
                            <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-receives-fda-fast-track-designation-for-crv431-for-the-treatment-of-nash/"
                                target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">November 30, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">All Endpoints Met in Drug-Drug Interaction Study with CRV431</h5>
                        <p class="card-text">Annouced results from a DDI study with its lead drug candidate, CRV431.</p>
                        <a href="https://hepionpharma.com/news/all-endpoints-met-in-hepion-pharmaceuticals-drug-drug-interaction-study-with-crv431/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">September 29, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Positive topline results from P2A AMBITION NASH</h5>
                        <p class="card-text">AMBITION trial acheives all primary endpoints, safety and tolerability.</p>
                        <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-positive-topline-data-from-phase-2a-ambition-nash-trial-all-primary-endpoints-achieved/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">July 13, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Hepion Pharmaceuticals to be Added to the Russell Microcap Index</h5>
                        <p class="card-text">Annouced that it is set to join the Russell Microcap Index at the
                            conclusion of the 2021 Russell indexes annual reconstitution.</p>
                        <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-to-be-added-to-the-russell-microcap-index/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">June 9, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Completes Final Patient Recruitment in P2A AMBITION NASH</h5>
                        <p class="card-text">Completed recruitment for its P2A AMBITION clinical trial for the treatment
                            of advanced NASH.</p>
                        <a href="https://hepionpharma.com/news/hepion-pharmaceuticals-completes-final-patient-recruitment-in-phase-2a-ambition-clinical-trial-of-crv431-for-the-treatment-of-advanced-nash/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">May 6, 2021</div>
                </div>
            </div>

            <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title">Positive results from DIAMOND Mouse Model Nonclinical Study</h5>
                        <p class="card-text">Annouced positive results from an in vivo study of CRV431 in a Diet-Induced
                            Animal Model of Non-Alcoholic Fatty Liver Disease ("DIAMOND').</p>
                        <a href="https://hepionpharma.com/news/diamond-mouse-model-is-latest-in-a-string-of-nonclinical-studies-confirming-the-antifibrotic-effects-of-hepion-pharmaceuticals-lead-drug-crv431/"
                            target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary">March 23, 2021</div>
                </div>
            </div>

            <!-- <div class="col-sm-6">
                <div class="card text text-center">
                    <div class="card-body">
                        <h5 class="card-title"></h5>
                        <p class="card-text"></p>
                        <a href="" target="_blank" class="btn btn-primary">Read Full</a>
                    </div>
                    <div class="card-footer text-body-secondary"></div>
                </div>
            </div> -->

        </div>
    </div>
    <br>
</body>

</html>